By Fineline Cube 
Akeso Biopharma (HKG: 9926) announced the signing of the Greater Bay Area Innovative Drug Charitable Donation Program with Hong Kong-based AccessRx, establishing a pioneering public welfare initiative to provide free, world-leading immunotherapy treatments to Hong Kong oncology patients facing financial barriers to medication access. The program has already entered the clinical screening phase for its first cohort of patients and aims to set a benchmark for pharmaceutical industry collaboration in the Guangdong-Hong Kong-Macao Greater Bay Area.
Program Structure & Implementation
| Component | Detail |
|---|---|
| Partnership | Akeso Biopharma + AccessRx (Hong Kong) |
| Geographic Scope | Guangdong-Hong Kong-Macao Greater Bay Area |
| Current Status | Clinical screening phase for first patient cohort |
| Delivery Mechanism | Hong Kong Named Patient Program (NPP) |
| Treatment Setting | Hong Kong public hospitals |
| Patient Eligibility | Financially disadvantaged lung cancer patients |
Drug Profile: Ivonescimab (Yidafang)
- Molecule: First-in-class PD-1/VEGF bispecific tumor immunotherapy
- Development: Independently developed by Akeso Biopharma
- Brand Name: Yidafang
- Mainland China Approvals:
- Locally advanced or metastatic non-squamous NSCLC progressing on EGFR-TKI therapy
- First-line treatment of advanced NSCLC with PD-L1-positive expression
- Mechanism: Dual targeting of PD-1 and VEGF pathways for enhanced anti-tumor activity
Hong Kong Named Patient Program (NPP) Framework
- Purpose: Special access mechanism for patients in urgent medical need
- Eligibility: Drugs approved overseas but not yet registered in Hong Kong
- Requirements: Must meet legal and ethical standards
- Clinical Oversight: Prescribed by qualified clinicians in public hospital settings
- Regulatory Context: Bridges access gap while formal registration process continues
Strategic Significance & Industry Impact
- Market Access Strategy: Accelerates patient access while pursuing formal Hong Kong regulatory approval
- Corporate Social Responsibility: Demonstrates commitment to equitable healthcare access across Greater Bay Area
- Regional Integration: Supports cross-border healthcare collaboration within national development strategy
- Competitive Differentiation: Positions Akeso as both innovator and accessibility advocate in premium oncology segment
- Precedent Setting: Establishes model for future charitable programs involving innovative biologics in Hong Kong
The charitable donation program represents Akeso’s dual commitment to innovation and accessibility, ensuring that cutting-edge immunotherapy reaches patients regardless of financial circumstances while building goodwill ahead of potential commercial launch in Hong Kong.
Forward-Looking Statements
This brief contains forward-looking statements regarding program implementation, regulatory pathways, and market access strategies. Actual outcomes may vary based on regulatory decisions, patient enrollment, and program execution.-Fineline Info & Tech